Rhythm Pharmaceuticals Stock Net Income
| RYTM Stock | USD 105.53 2.14 2.07% |
As of the 28th of January, Rhythm Pharmaceuticals holds the Coefficient Of Variation of (223,240), variance of 10.21, and Risk Adjusted Performance of 0.0074. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rhythm Pharmaceuticals, as well as the relationship between them. Please check Rhythm Pharmaceuticals market risk adjusted performance and treynor ratio to decide if Rhythm Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 105.53 per share. Given that Rhythm Pharmaceuticals has information ratio of (0.03), we recommend you to check out Rhythm Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.
Rhythm Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 38.0579 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -234.5 M | -222.8 M | |
| Net Loss | -234.5 M | -222.8 M | |
| Net Loss | -163 M | -154.9 M | |
| Net Loss | (4.91) | (4.67) | |
| Net Income Per E B T | 0.90 | 0.78 |
Rhythm | Net Income | Build AI portfolio with Rhythm Stock |
Latest Rhythm Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Rhythm Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Rhythm Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Rhythm Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Rhythm Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rhythm Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (260.6 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Rhythm Net Income Regression Statistics
| Arithmetic Mean | (96,714,442) | |
| Coefficient Of Variation | (92.92) | |
| Mean Deviation | 79,071,226 | |
| Median | (68,007,000) | |
| Standard Deviation | 89,863,263 | |
| Sample Variance | 8075.4T | |
| Range | 254.1M | |
| R-Value | (0.91) | |
| Mean Square Error | 1488.9T | |
| R-Squared | 0.83 | |
| Slope | (16,184,702) | |
| Total Sum of Squares | 129206.5T |
Rhythm Net Income History
Other Fundumenentals of Rhythm Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Rhythm Pharmaceuticals Net Income component correlations
Rhythm Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Rhythm Pharmaceuticals is extremely important. It helps to project a fair market value of Rhythm Stock properly, considering its historical fundamentals such as Net Income. Since Rhythm Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rhythm Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rhythm Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Rhythm Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rhythm Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rhythm Pharmaceuticals.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Rhythm Pharmaceuticals on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Rhythm Pharmaceuticals or generate 0.0% return on investment in Rhythm Pharmaceuticals over 90 days. Rhythm Pharmaceuticals is related to or competes with Revolution Medicines, Avidity Biosciences, Protagonist Therapeutics, Stoke Therapeutics, Uniqure NV, Rocket Pharmaceuticals, and Solid Biosciences. Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercializa... More
Rhythm Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rhythm Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rhythm Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 18.69 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 4.03 |
Rhythm Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rhythm Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rhythm Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Rhythm Pharmaceuticals historical prices to predict the future Rhythm Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0074 | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.01) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rhythm Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rhythm Pharmaceuticals January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0074 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 2.38 | |||
| Coefficient Of Variation | (223,240) | |||
| Standard Deviation | 3.2 | |||
| Variance | 10.21 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 18.69 | |||
| Value At Risk | (5.14) | |||
| Potential Upside | 4.03 | |||
| Skewness | 0.4436 | |||
| Kurtosis | 2.39 |
Rhythm Pharmaceuticals Backtested Returns
Rhythm Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0126, which implies the firm had a -0.0126 % return per unit of risk over the last 3 months. Rhythm Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Rhythm Pharmaceuticals' Risk Adjusted Performance of 0.0074, coefficient of variation of (223,240), and Variance of 10.21 to confirm the risk estimate we provide. The company holds a Beta of 0.91, which implies possible diversification benefits within a given portfolio. Rhythm Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Rhythm Pharmaceuticals is expected to follow. At this point, Rhythm Pharmaceuticals has a negative expected return of -0.0421%. Please make sure to check Rhythm Pharmaceuticals' treynor ratio, as well as the relationship between the accumulation distribution and period momentum indicator , to decide if Rhythm Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.14 |
Insignificant predictability
Rhythm Pharmaceuticals has insignificant predictability. Overlapping area represents the amount of predictability between Rhythm Pharmaceuticals time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rhythm Pharmaceuticals price movement. The serial correlation of 0.14 indicates that less than 14.0% of current Rhythm Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.14 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 21.96 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Rhythm Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Rhythm Pharmaceuticals reported net income of (260.6 Million). This is 176.36% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 145.64% higher than that of the company.
Rhythm Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rhythm Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rhythm Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rhythm Pharmaceuticals by comparing valuation metrics of similar companies.Rhythm Pharmaceuticals is currently under evaluation in net income category among its peers.
Rhythm Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rhythm Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rhythm Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Rhythm Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Rhythm Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Rhythm Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rhythm Pharmaceuticals' value.| Shares | Westfield Capital Management Company, L.p. | 2025-06-30 | 1.6 M | Hhg Plc | 2025-06-30 | 1.4 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 1.3 M | Geode Capital Management, Llc | 2025-06-30 | 1.3 M | Driehaus Capital Management Llc | 2025-06-30 | 1.3 M | Polar Capital Holdings Plc | 2025-06-30 | 1.3 M | Checkpoint Capital Lp | 2025-06-30 | 1.1 M | Alkeon Capital Management, Llc | 2025-06-30 | 1 M | Rock Springs Capital Management Lp | 2025-06-30 | 861.2 K | Blackrock Inc | 2025-06-30 | 6.3 M | Baker Bros Advisors Lp | 2025-06-30 | 5.6 M |
Rhythm Fundamentals
| Return On Equity | -0.86 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (1.03) % | ||||
| Current Valuation | 6.63 B | ||||
| Shares Outstanding | 66.74 M | ||||
| Shares Owned By Insiders | 0.64 % | ||||
| Shares Owned By Institutions | 99.36 % | ||||
| Number Of Shares Shorted | 6.2 M | ||||
| Price To Book | 46.36 X | ||||
| Price To Sales | 40.40 X | ||||
| Revenue | 130.13 M | ||||
| Gross Profit | 155.86 M | ||||
| EBITDA | (238.09 M) | ||||
| Net Income | (260.6 M) | ||||
| Cash And Equivalents | 235.6 M | ||||
| Cash Per Share | 4.64 X | ||||
| Total Debt | 3.94 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 5.59 X | ||||
| Book Value Per Share | 2.23 X | ||||
| Cash Flow From Operations | (113.88 M) | ||||
| Short Ratio | 6.48 X | ||||
| Earnings Per Share | (3.10) X | ||||
| Price To Earnings To Growth | 0.75 X | ||||
| Target Price | 141.57 | ||||
| Number Of Employees | 283 | ||||
| Beta | 2.01 | ||||
| Market Capitalization | 7.04 B | ||||
| Total Asset | 392.27 M | ||||
| Retained Earnings | (1.16 B) | ||||
| Working Capital | 258.68 M | ||||
| Net Asset | 392.27 M |
About Rhythm Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rhythm Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rhythm Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rhythm Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Rhythm Pharmaceuticals Piotroski F Score and Rhythm Pharmaceuticals Altman Z Score analysis. To learn how to invest in Rhythm Stock, please use our How to Invest in Rhythm Pharmaceuticals guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rhythm Pharmaceuticals. If investors know Rhythm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rhythm Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.10) | Revenue Per Share | Quarterly Revenue Growth 0.543 | Return On Assets | Return On Equity |
The market value of Rhythm Pharmaceuticals is measured differently than its book value, which is the value of Rhythm that is recorded on the company's balance sheet. Investors also form their own opinion of Rhythm Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rhythm Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rhythm Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rhythm Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rhythm Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rhythm Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rhythm Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.